Results 1 to 10 of about 366 (106)

Association of apolipoprotein E variants on Alzheimer's disease in Latin America: A systematic review and meta-analysis. [PDF]

Alzheimers Dement
Abstract The apolipoprotein E (APOE) ε4 allele represents the strongest genetic risk factor for Alzheimer's disease (AD), but its role in genetically diverse Latin American and Caribbean (LAC) populations is underexplored. We conducted a meta‐analysis of 35 studies from 11 LAC countries, encompassing 3206 patients with AD and 5515 controls.
Orellana P, Caviedes A, Gonzalez L, Ochoa-Rosales C, Carmona D, González-Silva C, Hernández H, Britton GB, Villarreal AE, Campos V, Hendrie H, Acosta-Uribe J, Pina-Escudero SD, Yokoyama JS, Vilor-Tejedor N, Parra M, Santamaria-García H, Ibañez A, de la Cruz R, Duran-Aniotz C.   +19 more
europepmc   +2 more sources

Single and multiple pathogen associations with cognitive impairment in the Panama Aging Research Initiative Study [PDF]

Alzheimers Dement
Abstract Background The prevalence of Alzheimer's disease (AD) in developing countries is expected to rise as a result of increases in life expectancy and the ageing of the population (1). Accumulating evidence implicates pathogens as triggers of inflammation and development of cognitive impairment and neurodegenerative disorders, including AD (2‐4 ...
Rangel G, Muñoz B, Ramirez M, Wroblewski K, Villarreal A, Oviedo D, Carreira M, McLeod R, Britton G.   +8 more
europepmc   +2 more sources

THE ROLE OF COGNITIVE RESERVE IN NEUROINFLAMMATION IN A PANAMANIAN SAMPLE [PDF]

Alzheimers Dement
Abstract Background Neurodegeneration is linked to cerebrovascular diseases (CVDs) that can impair daily functioning and accelerate cognitive decline in older adults. Blood‐based biomarkers reflect neuroinflammation and cerebrovascular pathology. While many individuals with CVDs experience lasting disabilities, cognitive reserve (CR)—strengthened by ...
Rodriguez‐Araña S, Oviedo D, Tratner A, Villarreal A, Rangel G, Britton G.   +5 more
europepmc   +2 more sources

Improving equity in Alzheimer's disease research: Biomarker disclosure in underserved populations [PDF]

Alzheimers Dement
Abstract Background The early diagnosis of Alzheimer's disease (AD) demands reliable biomarkers and accessible detection methods. Evidence shows that combining brain imaging with cerebrospinal fluid (CSF) biomarkers significantly enhances the sensitivity and specificity of AD diagnosis.
Oviedo D, Haughbrook R, Culjat C, Villarreal A, Ramirez L, Carreira M, Batista O, Harmon S, Meng Z, Tratner A, Hall C, Millender E, Britton G.   +12 more
europepmc   +2 more sources

The influence of APOEε4 on cognition in Hispanics: The Panama Aging Research Initiative ‐ Health Disparities Study [PDF]

Alzheimers Dement
Abstract Background The apolipoprotein E (APOE) gene is a well‐established risk factor for Alzheimer's disease. This study aims to investigate the relationship between APOE genotype and cognitive aging in a sample of Hispanics. We also present data from the research protocol of an ongoing clinical study within the PARI‐HD program. The main objective is
Villarreal A, Rangel G, Tratner A, Oviedo D, Carreira M, O'Bryant S, Sanchez E, Rodriguez C, Fletcher J, Ramírez A, Arosemena‐Aguero X, Araujo P, de Roux R, Balaguer R, Díaz M, Novarro‐Escudero N, Tamayo D, Aguilar L, Villarreal J, Mendoza J, Billingslea V, Juárez J, Courville K, Degracia S, Torres H, Benzadon A, Hammerschlag B, Saldaña A, Girón L, Solís D, Castillo L, Dondis D, Sucre F, Adames A, Crespo A, Rodriguez S, López N, Britton G.   +37 more
europepmc   +2 more sources

Effects of a non‐pharmacological program combining physical and cognitive interventions in older adults in Panama [PDF]

Alzheimers Dement
Abstract Background Currently, pharmacological interventions to delay cognitive decline in older adults have proven to be insufficient. Non‐pharmacological approaches, however, are gaining attention for improving cognition, enhancing well‐being, and alleviating caregiver burden.
Quiros E, Oviedo D, Britton G, Jones H, Juárez J, Villarreal A, Rangel G, Rodriguez S, Lammie S, Miranda S, Martínez M, Ortega E, Betancourt A, López N.   +13 more
europepmc   +2 more sources

Alzheimer diseases CSF biomarkers correlate with systemic biomarkers in a cohort of Hispanics [PDF]

Alzheimers Dement
Abstract Background We are conducting a biomarker‐based study to describe the demographic and biomarker profiles of Panamanians. The objective of this report is to present the main findings on CSF, genetic and serological biomarkers’ distribution and their association with cognition in a cohort of elderly people in Panama.
Villarreal A, Oviedo D, Carreira M, Rangel G, Araujo P, de Roux R, Balaguer R, Díaz M, Novarro‐Escudero N, Tamayo D, Villarreal J, Dondis D, Benzadon A, Britton G.   +13 more
europepmc   +2 more sources

Effects of a cognitive and physical intervention program in older adults in Panama [PDF]

Alzheimers Dement
Abstract Background Dementia affects nearly 50 million people worldwide and is the leading cause of disability in older adults. According to predictions by the World Health Organization, the global population with dementia will reach 82 million by 2030, and 152 million by 2050.
Quiros E, Oviedo D, Britton G, Rangel G, Villarreal A, Juárez J, Jones H.   +6 more
europepmc   +2 more sources

Prospective cohort study to evaluate the diagnostic values of biomarkers in blood, cerebrospinal fluid and magnetic resonance imaging for mild cognitive impairment, Alzheimer's disease and Parkinson's disease in Hispanics [PDF]

Alzheimers Dement
Abstract Background By 2025, an estimated three‐quarters of the global population aged 60 and older will live in Latin American and Caribbean countries (LAC), leading to a rise in age‐related conditions. The main goal of the Panama Aging Research Initiative – Health Disparities (PARI‐HD) research program is to create a platform for multidisciplinary ...
Fletcher J, Cano E, Ramírez A, Arosemena‐Aguero X, Araujo P, de Roux R, Balaguer R, Díaz M, Novarro‐Escudero N, Tamayo D, Aguilar L, Villarreal J, Mendoza J, Billingslea V, Juárez J, Courville K, Degracia S, Torres H, Benzadon A, Hammerschlag B, Saldaña A, Girón L, Solís D, Castillo L, Dondis D, Adames A, Crespo A, Araña S, Rodriguez C, López N, Oviedo D, Carreira M, Rangel G, Villarreal A, Britton G.   +34 more
europepmc   +2 more sources

Experiences in the use of multiple doses of convalescent plasma in critically ill patients with COVID-19: An early phase 1 descriptive study. [PDF]

Health Sci Rep
Abstract Background At the beginning of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) pandemic, transfusion of coronavirus disease 2019 (COVID‐19) convalescent plasma (CCP) emerged as a potential therapeutic strategy to help patients severely afflicted by COVID‐19.
Aguilar R, López-Vergès S, Quintana A, Morris J, Lopez L, Cooke A, Quiel D, Buitron N, Pérez Y, Lobo L, Ballesteros M, Pitti Y, Diaz Y, Saenz L, Franco D, Castillo D, Valdespino E, Blanco I, Romero E, Villarreal A, Cubilla-Batista I.   +20 more
europepmc   +2 more sources